×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Inogen, Inc. (NASDAQ:INGN) Receives Consensus Rating of "Hold" from Brokerages

Thursday, June 23, 2022 | MarketBeat

Shares of Inogen, Inc. (NASDAQ:INGN - Get Rating) have earned a consensus recommendation of "Hold" from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $41.00.

Several research analysts have recently issued reports on INGN shares. TheStreet downgraded Inogen from a "c-" rating to a "d" rating in a research note on Friday, March 11th. StockNews.com downgraded Inogen from a "hold" rating to a "sell" rating in a research note on Thursday, May 12th. Finally, Stifel Nicolaus reduced their target price on Inogen from $40.00 to $30.00 in a report on Monday, May 9th.

Shares of NASDAQ INGN opened at $25.18 on Thursday. The company has a market cap of $575.01 million, a price-to-earnings ratio of -28.61 and a beta of 1.01. Inogen has a 12 month low of $22.51 and a 12 month high of $82.35. The stock has a 50-day moving average price of $25.72 and a two-hundred day moving average price of $29.74.


Inogen (NASDAQ:INGN - Get Rating) last released its quarterly earnings data on Thursday, May 5th. The medical technology company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.10. Inogen had a negative return on equity of 3.83% and a negative net margin of 5.64%. The company had revenue of $80.39 million during the quarter, compared to the consensus estimate of $76.56 million. During the same quarter in the prior year, the firm posted ($0.03) earnings per share. The firm's revenue was down 7.5% compared to the same quarter last year. As a group, equities research analysts forecast that Inogen will post -1.63 EPS for the current year.

A number of hedge funds have recently made changes to their positions in INGN. US Bancorp DE boosted its holdings in shares of Inogen by 273.0% during the 1st quarter. US Bancorp DE now owns 884 shares of the medical technology company's stock worth $28,000 after buying an additional 647 shares in the last quarter. Captrust Financial Advisors boosted its holdings in shares of Inogen by 124.7% during the 1st quarter. Captrust Financial Advisors now owns 993 shares of the medical technology company's stock worth $32,000 after buying an additional 551 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Inogen by 64.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,280 shares of the medical technology company's stock worth $38,000 after buying an additional 500 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Inogen by 84,900.0% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 1,700 shares of the medical technology company's stock worth $55,000 after buying an additional 1,698 shares in the last quarter. Finally, Point72 Hong Kong Ltd bought a new position in shares of Inogen during the 3rd quarter worth approximately $81,000. Institutional investors and hedge funds own 96.01% of the company's stock.

About Inogen (Get Rating)

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Inogen right now?

Before you consider Inogen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.

While Inogen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:


Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastHow To Navigate The Market Downturn Like A Pro

In this episode, Kate sits down with Kyrill Astur, CEO of portfolio management firm Centerfin. Kyrill brings a background from Wall Street and hedge funds to his current role helping individual investors navigate the market challenges while investing for their future.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.